These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 29157298)

  • 1. Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection?
    Dos Santos Fernandes G; da Motta Girardi D; Dib Batista Bugiato Faria L; Giacomini Bernardes JP; de Almeida Coudry R
    J Immunother Cancer; 2017 Nov; 5(1):84. PubMed ID: 29157298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab for the treatment of gastric cancer.
    Kamath SD; Kalyan A; Benson AB
    Expert Rev Anticancer Ther; 2018 Dec; 18(12):1177-1187. PubMed ID: 30280940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.
    Taieb J; Moehler M; Boku N; Ajani JA; Yañez Ruiz E; Ryu MH; Guenther S; Chand V; Bang YJ
    Cancer Treat Rev; 2018 May; 66():104-113. PubMed ID: 29730461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints.
    Alsina M; Moehler M; Hierro C; Guardeño R; Tabernero J
    Target Oncol; 2016 Aug; 11(4):469-77. PubMed ID: 26880697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translating gastric cancer genomics into targeted therapies.
    Ang YL; Yong WP; Tan P
    Crit Rev Oncol Hematol; 2016 Apr; 100():141-6. PubMed ID: 26947813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gastric cancer and the epoch of immunotherapy approaches.
    Niccolai E; Taddei A; Prisco D; Amedei A
    World J Gastroenterol; 2015 May; 21(19):5778-93. PubMed ID: 26019442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of gene copy number instability and tumor mutation burden in patients with resectable gastric cancer.
    Cai L; Li L; Ren D; Song X; Mao B; Han B; Zhang H
    Cancer Commun (Lond); 2020 Jan; 40(1):63-66. PubMed ID: 32141230
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development.
    Abozeid M; Rosato A; Sommaggio R
    Biomed Res Int; 2017; 2017():5791262. PubMed ID: 28781967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
    JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for oesophagogastric cancer.
    Davidson M; Chau I
    Expert Opin Biol Ther; 2016 Oct; 16(10):1197-207. PubMed ID: 27409159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Implications of TCGA Network Data on 2nd Generation Immunotherapy Concepts Based on PD-L1 and PD-1 Target Structures].
    Peters I; Tezval H; Kramer MW; Wolters M; Grünwald V; Kuczyk MA; Serth J
    Aktuelle Urol; 2015 Nov; 46(6):481-5. PubMed ID: 26560846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy.
    Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B
    Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival.
    Budczies J; Bockmayr M; Denkert C; Klauschen F; Gröschel S; Darb-Esfahani S; Pfarr N; Leichsenring J; Onozato ML; Lennerz JK; Dietel M; Fröhling S; Schirmacher P; Iafrate AJ; Weichert W; Stenzinger A
    Genes Chromosomes Cancer; 2016 Aug; 55(8):626-39. PubMed ID: 27106868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for gastric cancers: emerging role and future perspectives.
    Bonotto M; Garattini SK; Basile D; Ongaro E; Fanotto V; Cattaneo M; Cortiula F; Iacono D; Cardellino GG; Pella N; Fasola G; Antonuzzo L; Silvestris N; Aprile G
    Expert Rev Clin Pharmacol; 2017 Jun; 10(6):609-619. PubMed ID: 28349740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics of Gastric Cancer.
    Strand MS; Lockhart AC; Fields RC
    Surg Clin North Am; 2017 Apr; 97(2):345-370. PubMed ID: 28325191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell therapy in advanced gastric cancer: a promising new hope?
    Tewari M; Sahai S; Mishra RR; Shukla SK; Shukla HS
    Surg Oncol; 2012 Sep; 21(3):164-71. PubMed ID: 22521560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive biomarkers along gastric cancer pathogenetic pathways.
    Panarese I; De Vita F; Ronchi A; Romano M; Alfano R; Di Martino N; Zito Marino F; Ferraraccio F; Franco R
    Expert Rev Anticancer Ther; 2017 May; 17(5):417-425. PubMed ID: 28277834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
    Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
    Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy.
    Giampieri R; Maccaroni E; Mandolesi A; Del Prete M; Andrikou K; Faloppi L; Bittoni A; Bianconi M; Scarpelli M; Bracci R; Scartozzi M; Cascinu S
    Gastric Cancer; 2017 Jan; 20(1):156-163. PubMed ID: 26796888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.